JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

145.98

+0.05%↑

JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

145.98

+0.05%↑

JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

145.98

+0.05%↑

JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

145.98

+0.05%↑

JNJ

192.81

+0.35%↑

ABT

127.86

+0.06%↑

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

145.98

+0.05%↑

Kodu・Aktsiate loetelu・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Suletud

SektorTervishoid

26.26 0.42

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

26.47

Põhinäitajad
By Trading Economics
Sissetulek	-5.8M 40M
Müük	16M 200M
P/E Sektori keskmine	8.367 37.461
Aktsiakasum	0.92
Kasumimarginaal	19.839
Töötajad	268
EBITDA	3M 59M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+70.34% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	28. okt 2025

Turustatistika
By TradingEconomics
Turukapital	-544M 1.5B
Eelmine avamishind	25.84
Eelmine sulgemishind	26.26

Uudiste sentiment

By Acuity

34%

66%

108 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

29.8 / N/A Toetus ja vastupanu

Harmony Biosciences Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. okt 2025, 22:47 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22. okt 2025, 22:13 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22. okt 2025, 21:20 UTC

Tulu

Correction to IBM 3Q Sales Jump Article

22. okt 2025, 20:57 UTC

Tulu

SAP Posts Higher 3Q Revenue, Operating Profit

22. okt 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22. okt 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22. okt 2025, 23:41 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22. okt 2025, 23:38 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22. okt 2025, 23:15 UTC

Tulu

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22. okt 2025, 22:28 UTC

Market Talk

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22. okt 2025, 22:02 UTC

Tulu

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22. okt 2025, 21:59 UTC

Omandamised, ülevõtmised, äriostud

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22. okt 2025, 21:58 UTC

Omandamised, ülevõtmised, äriostud

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22. okt 2025, 21:57 UTC

Omandamised, ülevõtmised, äriostud

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22. okt 2025, 21:56 UTC

Omandamised, ülevõtmised, äriostud

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22. okt 2025, 21:47 UTC

Omandamised, ülevõtmised, äriostud

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22. okt 2025, 21:47 UTC

Tulu

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22. okt 2025, 21:47 UTC

Omandamised, ülevõtmised, äriostud

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22. okt 2025, 21:46 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22. okt 2025, 21:45 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22. okt 2025, 21:45 UTC

Omandamised, ülevõtmised, äriostud

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22. okt 2025, 21:28 UTC

Market Talk

Tulu

Correction to Alcoa Tariff Market Talk

22. okt 2025, 21:25 UTC

Tulu

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22. okt 2025, 21:17 UTC

Tulu

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22. okt 2025, 21:09 UTC

Market Talk

Tulu

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22. okt 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

22. okt 2025, 20:59 UTC

Tulu

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22. okt 2025, 20:51 UTC

Tulu

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22. okt 2025, 20:44 UTC

Tulu

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Võrdlus sarnastega

Hinnamuutus

Harmony Biosciences Holdings Inc Prognoos

Hinnasiht

By TipRanks

70.34% tõus

12 kuu keskmine prognoos

Keskmine 44.56 USD 70.34%

Kõrge 62 USD

Madal 31 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Harmony Biosciences Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi Harmony Biosciences Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

29.8 / N/AToetus ja vastupanu

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

108 / 371 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.